AUSTIN, Texas, Feb. 13, 2025 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene Corporation (NYSE: CNC), announced it has been named a Best Place for Working Parents® for a fifth consecutive year. This designation is supported by Early Matters Greater Austin, a joint initiative from United Way for Greater Austin and E3 Alliance.
"Supporting working parents with family-friendly resources, policies, and benefits, continues to be a priority for our organization," said Mark Sanders, Superior HealthPlan president and CEO. "This designation signifies our commitment to that approach, one that I believe allows us to elevate our ability to provide quality healthcare to the nearly two million people we serve across Texas."
In 2019, Superior was one of the first organizations in Austin to be recognized as a Family-Friendly Workplace. Ever since, Superior has been named a Best Place for Working Parents®, adding multiple benefits aimed at further supporting employees:
To learn more about the designation, visit https://bestplace4workingparents.com/.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality health care throughout Texas. Committed to transforming the health of the community, one person at a time, Superior supports active local involvement in all 254 Texas counties with 3,300 employees throughout the state. Superior is a company of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. More information on Superior can be found at www.SuperiorHealthPlan.com.
Last Trade: | US$54.07 |
Daily Change: | 0.56 1.05 |
Daily Volume: | 2,649,267 |
Market Cap: | US$27.300B |
April 25, 2025 February 24, 2025 February 04, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load